Medacta receives US clearance for ACDF procedures

Medacta has received clearance from the US Food and Drug Administration (FDA) for a plate that allows vertebrae to be fused together as part of anterior cervical discectomy and fusion (ACDF) procedures. The Mecta-C Stand Alone Anterior Cervical Interbody Fusion Device is to be used to surgically treat herniated discs in the cervical spine area. 

As the Ticino-based Medacta explained in a press release, this device will offer the benefits of an anterior plate that is inserted through the throat area. In addition, the versatile screw system requires no additional fixation. The modular design of the Mecta-C Stand Alone system is an important feature as it allows surgeons to select between four different plate options during the operation. In this way, various requirements and patient anatomies can be optimally taken into account.

Medacta is an international company founded in 1999. Its headquarters are located in Castel San Pietro near to Mendrisio. It specializes in the development and production of innovative orthopedic products. Furthermore, it has a focus on the development of surgical techniques for joint replacement procedures, spinal operations and sports medicine. In April 2019, Medacta concluded an IPO and is now listed on the Six Swiss Exchange.